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Portopulmonary hypertension (PoPH) is a well-recognized
complication of portal hypertension (PH). PoPH has a great
impact on quality of life, survival, and suitability for liver
transplantation. The aim of this article is to provide a
detailed discussion concerning the epidemiology, diagnosis,
treatment and clinical significance of PoPH.
Historical background
In 1951, Mantz and Craige reported a peculiar case of a 53-
year old woman who expired while undergoing a thoracot-
omy for hematemesis [1]. The authors noted that the pa-
tient’s pulmonary artery was enlarged and exhibited
forceful pulsations more characteristic of the aorta than of
the typically low-pressure pulmonary trunk. The intra-
operative findings and subsequent autopsy revealed a ste-
notic portal vein, a portocaval shunt, and esophageal
varices. The pulmonary arteries demonstrated intimal
thickening, endothelial proliferation and thrombotic
changes. In retrospect, this patient suffered from what
subsequently became known as portopulmonary hyperten-
sion-a syndrome characterized by pulmonary hypertension
in the setting of portal hypertension.
On the basis of this initial description, it was unclear if
the association of portal hypertension and pulmonary hy-
pertension was coincidental. However, subsequent reports
of similar cases suggested that there was an undeniable
relationship between the two conditions. Initially, the
observation that PoPH was a distinct clinical entity did not
have major practical implications because treatment for
pulmonary hypertension and advanced liver disease was not
yet available. However, today, in the era of pulmonaryvasodilators and orthotopic liver transplantation, the
diagnosis of PoPH is imperative as current treatment may
improve symptoms, function, and survival.Definition
The World Health Organization (WHO) classifies PoPH as a
form of Group 1 (pulmonary arterial hypertension): mean
pulmonary arterial pressure (mPAP) > 25 mmHg and pul-
monary artery occlusive pressure (PaOP) < 15 mmHg at
rest.
PoPH is defined as pulmonary arterial hypertension
associated with portal hypertension. The traditional WHO
definition of pulmonary arterial hypertension does not
require that the pulmonary vascular resistance (PVR)
exceed any particular value. This is because in the setting
of a normal or decreased cardiac output, an increased
mPAP implies an increased PVR. However, patients with
liver disease often develop an abnormally high cardiac
output that can result in an elevated pulmonary artery
pressure without a concomitant increase in the PVR
because of the phenomena of pulmonary vascular recruit-
ment and distention.
Some authors have questioned if the diagnosis of PoPH
can be made in the absence of an increased PVR and have
labeled this phenomenon as a “hyperdynamic state” [2]. In
2004, the European Respiratory Society (ERS) guidelines
required that the PVR exceed 240 dyn s cm5 for the
diagnosis of PoPH [3]. The guidelines acknowledged that
this PVR cut-off value was arbitrary. PoPH patients who
have a PVR >240 dyn s cm5 clearly exhibit intimal thick-
ening, smooth muscle hypertrophy and plexiform lesions in
the pulmonary vasculature similar to other forms of PAH.
Plexiform changes have not been documented in patients
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decreased compliance of the pulmonary vasculature in
relation to the cardiac output. It remains conjectural
whether these patients exhibit pathological vascular
changes of PAH or if they are at high risk of developing such
pathology. We will henceforth adopt the ERS definition and
the diagnosis of PoPH shall imply a PVR >240 dyn s cm5.Pathogenesis
Although the pathological changes in the pulmonary
vasculature observed with PoPH are similar to other types
of WHO Group 1 pulmonary arterial hypertension, the
mechanisms involved in the development of PoPH remain
poorly understood [4]. PoPH is an uncommon complication
of liver disease; furthermore, there is a weak association
between pulmonary hypertension and the severity of liver
disease [5,6]. A “multi-hit hypothesis” proposed to explain
the mechanism of other types of pulmonary hypertension
may also apply to PoPH [7]. According to this hypothesis,
genetically predisposed individuals (first “hit”) develop a
pulmonary vasculopathy resulting in intimal proliferation,
medial thickening and plexogenic changes when subjected
to additional environmental or genetic factors (second
“hits”). In the case of PoPH, the necessary second “hit”
may result from additional genetic factors, vasoactive
metabolites that are inadequately metabolized by the liver,
and pulmonary vascular stress induced by an increased
cardiac output associated with liver disease. These poten-
tial mechanisms will be discussed subsequently.Genetic factors
Several gene polymorphisms including bone morphogenetic
protein receptor 2 (BMPR2) and other ligands belonging to
the transforming growth factor b1 (TGF-b1) family are
responsible for a significant proportion of hereditary PAH
cases. However, these mutations do not appear to be
associated with PoPH [3]. Data on gene polymorphisms
associated with PoPH are very limited [8,9]. Only one study
substantiated associations between PoPH and specific geneTable 1 Genetic factors associated with PoPH.
Affected pathways Specific gene polymorphism
Nitric oxide metabolism Phosphodiestherase-5
Nitric oxide synthase
Estrogen metabolism Aromatase
Estrogen receptor-1
Angiogenesis Various genetic polymorphi
Intracellular signaling Polymorphisms of S100 calc
Others Retinoic acid receptor beta
Caveolin-1
Xanthine dehydrogenase
Superoxide dismutase
NADPH oxidase-4
Plasminogen activator inhib
PoPH-portopulmonary hypertension; NADPH-nicotinamide adenine dinpolymorphisms in 31 PoPH cases and 104 controls (advanced
liver disease without evidence of PoPH) (Table 1) [8].
Vasoactive metabolites
Portal hypertension results in collateral circulation and
shunts that drain the splanchnic bed directly into the sys-
temic venous circulation and subsequently to the pulmo-
nary circulation, bypassing metabolism in the liver. Failure
of the liver to metabolize vasoactive substances has been
considered a rational, although unproven mechanism to
cause PoPH [10]. Increased serum concentrations of many
vasoactive substances have been found in portal hyper-
tension, though the specific offending metabolites remain
unproven. A potential role for several of these substances
in the development of PoPH is summarized in Table 2.
Vascular stress
A low systemic vascular resistance (SVR) commonly occurs
with liver disease. The low SVR causes a compensatory in-
crease in the cardiac output, occasionally up to 2-3-fold.
The mechanism of low SVR involves vasodilatation that is
either diffuse or limited to the splanchnic circulation [29].
The increased cardiac output augments pulmonary blood
flow and may potentially cause stress of the vascular
endothelial layer.
The mechanisms of pulmonary vasculature compensa-
tion for the high flow/hyperdynamic state remain contro-
versial [30]. It is known that as the cardiac output rises, the
resistance of the pulmonary vasculature decreases rapidly
so that pulmonary pressures return to normal or near-
normal levels. This response occurs within 60 min with
moderate exercise. [31] Most situations that demand a high
cardiac output are temporary (exercise, fever, distributive
shock). Although this compensatory response of the pul-
monary vascular bed is usually maintained for a prolonged
period of time, persistent circulatory overload could
potentially exhaust the compensatory mechanisms result-
ing in irreversible vascular changes of pulmonary hyper-
tension. Studies demonstrating a wide variation in the
pulmonary vascular response to increases in cardiac outputs Associated risk for PoPH
Increased
Decreased
Increased
Increased or decreased
sms of angiopoietin-1 Increased or decreased
ium binding protein A4 Increased
itor-1
Increased or decreased
ucleotide phosphate.
Table 2 Roles of mediators in PoPH.
Mediator Serum level of mediator elevated
in cirrhosis
Evidence References
Endothelin-1 Yes, especially with portal
hypertension and ascites.
Higher levels of ET-1 are a risk factor for PoPH independent
of the severity of portal hypertension.
[11e13]
Glucagon Yes Glucagon increases portal blood flow and attenuates
mediators of vasoconstriction causing a hyperdynamic
state/pulmonary vascular stress.
[14,15]
VIP Yes VIP is 100-times more potent than acetylcholine as a
splanchnic and peripheral vasodilator and may induce
vascular stress.
[16e19]
Serotonin Yes. Also elevated in idiopathic
pulmonary hypertension.
Serotonin has been implicated in PAH related to
anorexigenic drug use.
Serotonin stimulates S100
A4 production (see Table 1).
[20e25]
Estrogens Yes with altered downstream
metabolism.
Genetic variations in both the estrogen receptors and
estrogen synthesis are associated with PoPH.
Cirrhosis-induced changes in estrogen metabolism
increases mitogenic activity in pulmonary vascular
smooth muscle cells.
[26e28]
PoPH-portopulmonary hypertension; ET-1-endothelin-1; VIP-vasoactive intestinal peptide; PAH-pulmonary arterial hypertension;
S100A4-S100 calcium binding protein A4.
946 B.I. Medarov et al.among normal individuals [32] suggest that only a per-
centage of individuals are susceptible to pulmonary
vascular damage from high cardiac output states. This
theory of vascular stress may be relevant in other types of
PAH associated with high cardiac output (hyperthyroidism,
chronic hemolytic anemia, left-to-right atrial shunt, AV
fistula) [33,34].Table 3 Causes of dyspnea in patients with liver disease.
Pulmonary Parenchymal Pulmonary edema
(volume overload,
renal failure)
Pneumonia
Extraparenchymal Pulmonary
hemorrhage
Pleural effusion
Hepatic hydrothorax
Ascites causing
lung restriction
Pulmonary
vascular
disease
PoPH
Hepatopulmonary
syndrome
Extrapulmonary Cirrhotic
cardiomyopathy
Anemia
Cirrhotic myopathy
Other common
causes of dyspnea
not related to liver
disease (obesity,
heart failure)
PoPH-portopulmonary hypertension.Epidemiology
PoPH accounts for approximately 5%e10% of all WHO Group
1 (pulmonary arterial hypertension) cases [35,36]. The
prevalence of PoPH in liver transplant candidates with
advanced cirrhosis may be as high as 8.5%, though most
cases are mild [37]. Prevalence rates as high as 16% have
been reported in decompensated patients with refractory
ascites [13]. Although liver cirrhosis is overwhelmingly the
most common cause of PoPH, it may occur in patients with
non-cirrhotic liver disease [10]. Female sex and autoim-
mune liver disease are associated with a higher risk of PoPH
(odds ratios 4 and 9.8 respectively) whereas hepatitis C
liver disease may be relatively protective of PoPH (odds
ratio 0.2) [6].
Clinical presentation
The symptoms and signs of PoPH are similar to those in
other types of pulmonary arterial hypertension. Exertional
dyspnea is the most frequent symptom, which is the pre-
senting complaint in more than 80% of cases. Syncope,
chest pain and fatigue are symptoms at presentation in less
than one third of the cases of PoPH. An accentuated pul-
monary component of the second heart sound (82%) and a
systolic murmur (69%) are the most common physical find-
ings [38]. Stigmata of portal hypertension may be present
including ascites, splenomegaly, esophageal varices,
“caput medusae”. In addition, signs of liver disease may be
present such as “spider” angiomata and palmar erythema.
Screening
Establishing the diagnosis of PoPH can be challenging
because the disease is uncommon, screening tests are
Figure 1 Diagnostic approach to PoPH in patients with
advanced liver disease. * see text; PH-pulmonary hypertension;
RVSP-right ventricular systolic pressure; mPAP-mean pulmo-
nary artery pressure; PVR-pulmonary vascular resistence;
PoPH-portopulmonary hypertension.
Clinical aspects of portopulmonary hypertension 947inexact and the diagnostic test is expensive and invasive.
Nevertheless, it is imperative to diagnose PoPH early in its
course as undetected disease may progress to a life-
threatening state and/or preclude liver transplantation.
All patients with portal hypertension reporting dyspnea
should be screened for PoPH. The presence of PoPH is
associated with an increased risk of perioperative morbidity
and mortality from liver transplantation [37]. Therefore, it
is imperative to screen for POPH in all liver transplantation
candidates.
Although PoPH is a potential cause of dyspnea in pa-
tients with portal hypertension, advanced liver disease may
result in dyspnea via many alternative mechanisms. A
detailed diagnostic evaluation should be performed to
exclude other potential causes of dyspnea (Table 3). Chest
imaging is useful in identifying hepatic hydrothorax,
cirrhosis-related cardiomyopathy or lung conditions unre-
lated to liver disease. Hepatopulmonary syndrome (HPS) is
another pulmonary vascular disease associated with
advanced liver disease. HPS is characterized by the pres-
ence of hypoxemia with an increased alveolarearterial
gradient (Aea gradient) and evidence of pulmonary
vascular dilation. The diagnosis of HPS is usually confirmed
by identifying the presence of an intrapulmonary shunt via
echocardiography: intravenous instillation of agitated sa-
line results in saline bubbles being visualized in the left
atrium three or more cardiac cycles after they appear in
the right atrium [3]. HPS and PoPH can coexist in the same
patient.
The following routine clinical test results may suggest
the possibility of PoPH: a) a chest radiograph showing
decreased retrosternal space (enlarged right ventricle) and
pruning of the pulmonary vasculature (large proximal ar-
teries and disproportionately small peripheral vessels); b)
an arterial blood gas revealing mild respiratory alkalosis
with an increased alveolar-arterial oxygen gradient; c) an
electrocardiogram demonstrating a right ventricular strain
pattern; d) pulmonary function tests demonstrating a
reduced diffusing capacity. None of these tests are sensi-
tive enough to be used as a screening tool for PoPH.
2-dimensional surface Doppler echocardiography (2D
Echo) is a universally accepted screening test for PoPH in
patients with portal hypertension [39]. 2D Echo not only
provides an estimate of right ventricular systolic pressure
(RVSP), but also indicates structural changes associated
with advanced pulmonary hypertension such as right-sided
cardiac chamber enlargement and right ventricular pres-
sure or volume overload. In a prospective study of patients
undergoing liver transplant evaluation, a RVSP estimate of
30 mmHg on 2D Echo had a 100% sensitivity and negative
predictive value for right-heart catheterization confirmed
pulmonary hypertension [40]. The positive predictive value,
however, proved to be poor at 59%. Based on the available
data, the ERS recommends that PAH should be considered
unlikely if the 2D Echo estimate of RVSP is  36 mmHg and
likely if the estimated RSVP is > 50 mmHg (Fig. 1) [41].
Unfortunately, an estimate of RVSP cannot always be
obtained from echocardiography because of an inadequate
tricuspid regurgitation jet. This scenario occurred in 22% of
PoPH patients in one echocardiographic study [5]. Trans-
esophageal echocardiography may be helpful in those
cases, especially in obese patients. If the echocardiogramestimate of RVSP is < 50 mmHg or cannot be determined,
right heart catheterization may be appropriate to evaluate
patients for pulmonary hypertension if other morphologic
features of the echocardiogram suggest pulmonary hyper-
tension (pulmonic valve insufficiency, paradoxical septal
motion, right ventricular hypertrophy/dilatation, poor
tricuspid annular systolic excursion) or the clinical suspicion
remains high (e.g., disproportionately severe dyspnea and/
or reduced DLCO compared to spirometry, physical findings
consistent with pulmonary hypertension, oxygen
Table 4 Summary of clinical trials on PoPH therapy.
Vasodilators N Study design Outcome Reference
Prostanoids Epoprostenol 15 Retrospective Long-term improvement in
hemodynamics
Krowka et el. [48]
19 Retrospective Improvement in hemodynamics,
no difference in survival
Fix et al. [49]
20 Prospective Improved eligibility for
successful OLT
Ashfaq et al. [50]
Treprostinil 3 Case series Improved hemodynamics Sakai et al. [55]
Ilioprost 21 Retrospective Rapid reduction in PAP and PVR Melgossa et al. [56]
12 Retrospective Long-term Improvement in NYHA
class and exercise capacity
ERA’s Bosentan 11 Prospective
case series
Improve exercise capacity
and hemodynamics
Hoeper et al. [60]
Ambrisentan 13 Prospective
case series
Improvement in hemodynamics
PAP, PVR. No adverse effects
on the liver
Cartin-Ceba et al. [63]
PDE-5 inhibitors Sildenafil 14 Retrospective Improved hemodynamics and
exercise capacity
Reichenberger et al. [64]
Tadalafil 1 Case report Improvement in PA pressures. Bremer et al. [67]
PoPH-portopulmonary hypertension; ERA-endothelin receptor antagonist; OLT-orthotopic liver transplantation; PAP-pulmonary arterial
pressure; PVR-pulmonary vascular resistance; NYHA-New York Heart Association; PDE-5-phosphodiestherase-5.
948 B.I. Medarov et al.desaturation with ambulation, diminished 6-min walk dis-
tance without an alternative clinical explanation).Diagnosis
The diagnosis of PoPH is established by right heart cathe-
terization. The following criteria are required: mean pul-
monary arterial pressure >25 mmHg; PaOP <15 mmHg; PVR
>240 dyn s cm5; evidence of portal hypertension (Fig. 1).
Patients meeting these criteria but demonstrating an
elevated PaOP deserve a special mention. This scenario
cannot be ascribed to pulmonary venous hypertension
alone considering the elevation of PVR and often indicates
a mixed etiology of pulmonary arterial hypertension and
pulmonary venous hypertension. Although an elevated
transpulmonary gradient (TPG, which equals mPAP-PaOP)
of >12 mmHg has been used to identify pulmonary arte-
rial hypertension in the presence of pulmonary venous hy-
pertension in other forms of pulmonary hypertension, this
finding is of limited value in identifying PoPH. This is
because the requirement that the PVR exceed
240 dyn s cm5 in PoPH implies that the TPG will be
elevated unless the cardiac output is lower than 4 L/min,
which is uncommon in advanced liver disease. Patients
showing this mixed form of pulmonary hypertension require
clinical judgment in terms of whether the arterial and/or
venous pulmonary hypertension should be treated; repeat
right heart catheterization after a successful diuresis may
be required for adequate management of these patients.Therapy
Therapy for PoPH is based on limited evidence and is often
extrapolated from trial of other forms of pulmonary hy-
pertension. Given these caveats, in this section we reportthe limited evidence and our recommendations for treat-
ment of PoPH.
Conventional PAH therapies
Long-term oxygen therapy
Mild hypoxemia is common in PoPH. In a study of 20 patients
with PoPH, 80% had an increased A-a gradient [42]. Hypox-
emia can worsen pulmonary hypertension; therefore, sup-
plemental oxygen therapy is recommended when the serum
partial oxygen pressure (PaO2) is < 60 mmHg at rest [3].
Diuretics
Diuretics are often used for the treatment of PH associated
volume overload or ascites. However, the RV is preload-
dependent and excessive diuresis may decrease preload
causing hypotension and systemic hypoperfusion. In addi-
tion, excessive diuresis in the setting of diminished effec-
tive arterial blood volume, which is common in advanced
cirrhosis, can result in kidney injury [43]. Therefore, di-
uretics should be cautiously used in PoPH.
Pulmonary vasodilator therapy
Vasodilator treatment of PoPH is still not standardized
because PoPH patients are typically excluded from PH tri-
als; therefore, clinical data are meager concerning this
condition (Table 4). As previously mentioned, the histo-
pathological findings of PH and PoPH are very similar [44].
For these reasons, the ERS has recommended that PoPH be
treated similarly to other forms of PAH [41]. In this section,
we discuss the limited clinical data and recommendations
concerning pulmonary vasodilator therapy for PoPH.
Prostanoids
Prostanoids have been used for the treatment for PH for
more than two decades [30]. Prostacyclin synthase is
Clinical aspects of portopulmonary hypertension 949reduced in PAH resulting in inadequate production of
prostacyclin that causes vasoconstriction and proliferative
changes in the pulmonary vasculature [45]. Prostanoids are
potent vasodilators with platelet anti-aggregation and
antiproliferative properties. Commercially available pros-
tanoids in the United States are epoprostenol, treprostinil
and iloprost.
Epoprostenol (EPO). EPO is an intravenous synthetic form
of prostacyclin. Because of its short half-life (w6 min), EPO
requires continuous infusion though a central access via an
infusion pump. In idiopathic pulmonary arterial hypertension
(IPAH), epoprostenol has shown to improve exercise
tolerance, hemodynamics, quality of life and survival
[46,47]. However, there are minimal data concerning EPO
therapy for PoPH and they are less promising. Although two
long-term retrospective studies of EPO treatment of PoPH
demonstrated that hemodynamic improvement was
sustained, there was no difference in survival [48,49]. Even
though no survival advantage has been demonstrated, EPO
may be used in patients with moderate to severe PoPH in
an effort to improve symptoms or improve the outcome of
liver transplantation (vide infra). EPO has been used as a
bridge to liver transplantation with satisfactory results
[49e51].
Common side effects of EPO include flushing, headache,
nausea/vomiting, hypotension, bradycardia, chest pain,
jaw pain, diarrhea and musculoskeletal pain [52]. EPO
infusion requires maintenance of aseptic techniques to
avoid blood stream infections. EPO pump failure or loss of
vascular access may lead to rebound pulmonary vasocon-
striction that can be life-threatening and requires imme-
diate attention. A few reports suggested that EPO may
cause ascites even without liver disease [53]. Worsening
splenomegaly and hypersplenism has also be observed in
PoPH patients treated with EPO [54].
Treprostinil. Treprostinil is a prostanoid that is available
in an intravenous, subcutaneous and inhalational form. In a
small case series of 3 patients with end stage liver disease
and PAH, long-term administration of intravenous
treprostinil was shown to improve hemodynamics [55].
Similar to EPO, treprostinil could be considered for the
treatment of moderate to severe PoPH.
Inhaled iloprost. Because inhaled iloprost has a short
therapeutic half-life of 20e30 min, it requires frequent
administration 6-9 times per day. A study of 21 PoPH
patients who received iloprost demonstrated a rapid
reduction in PAP and PVR without any significant change
in cardiac output, or hepatic venous pressure gradient [56].
These authors also found that the use of inhaled iloprost for
PoPH improved WHO functional class and the 6-min walk
distance (6MWD) at 12 months. Inhaled iloprost can be
considered for the treatment of PoPH in patients capable
of using this medication at its demanding dosing schedule.
Endothelin receptor antagonists (ERAs)
ERA drugs block the production of endothelin-1 (ET-1), a
vasoconstrictor and a smooth muscle mitogen that may
contribute to the development of PAH. Elevated ET-1 con-
centrations have been reported in patients with advancedliver cirrhosis, and there is accumulating evidence that ET-1
may originate from the hepatosplanchnic circulation
[11,57]. Several studies have shown that plasma levels of
ET-1 are increased in PAH and correlate with severity and
prognosis of PAH [58,59].
Bosentan. Bosentan is an oral, dual ET-1A and ET-1B re-
ceptor antagonist. There is a paucity of information con-
cerning bosentan for the treatment of PoPH due to the risk
of hepatotoxicity from this drug. In a small prospective case
series (nZ 11) and single case reports, bosentan was shown
to improve exercise capacity, hemodynamics with good
tolerance and without drug related toxicities [60e62].
Ambrisentan. Ambrisentan is a highly selective ET-1A re-
ceptor antagonist. Advantages of ambrisentan over bosentan
include once daily dosing and a lower risk of hepatotoxicity.
In a small observational study of 13 PoPH patients, mono-
therapy with ambrisentan was associated with significant
improvement in mPAP and PVR without adverse effects on
hepatic function [63]. Presently, although there are
inadequate data to routinely recommend ERA’s for the
treatment of POPH, those agents can be considered, and
ambrisentan is preferred over bosentan.
Phosphodiesterase-5 (PDE-5) inhibitors
PDE-5 inhibitors prolong the vasodilatory effects of cyclic
guanosine monophosphate (cGMP) by preventing its hydro-
lysis. PDE-5 inhibitors are commonly used for the treatment
of PAH.
Sildenafil. Sildenafil has been used extensively in the
treatment of PAH. Sildenafil alone or in combination with
inhaled prostanoids significantly increased mean 6MWD and
cardiac index as well as reduced mPAP, PVR and mean pro-
brain-natriuretic-peptide levels in PoPH patients [64].
However, the hemodynamic improvements were not
sustained at 12 months. In very small observational studies,
sildenafil monotherapy has shown to improve pulmonary
hemodynamics in liver transplant candidates, and may
thereby facilitate liver transplantation [65,66]. Although
these data are not conclusive, in our opinion, sildenafil can
be used as monotherapy in mild cases of PoPH and in
combination with prostanoids in moderate to severe PoPH.
Tadalafil. Tadalafil is an oral PDE-5 inhibitor with longer
half-life than sildenafil so that it requires once daily
administration. To date, only one case describing
treatment of PoPH has been reported that showed a small
improvement in portal venous and pulmonary artery
pressures [67]. We believe that the role for tadalafil in
the treatment of PoPH is similar to that of sildenafil.
Drugs not routinely recommended for PoPH
Calcium channel blockers (CCB)
Vasodilator testing during right heart catheterization is
often performed in patients with PAH to determine the
vasoreactive subgroup that may benefit from long-term
CCB. However, the only data on CCB in PoPH consist of a
retrospective study of 153 patients where just 2 (1.3%)
950 B.I. Medarov et al.patients were vasoreactive and 1 of the 2 had a long-term
sustained response with CCB [68]. In addition, CCB can
cause splanchnic vasodilation that could, theoretically, in-
crease the risk of variceal bleeding by raising the hepatic
venous pressure gradient and portal vein bloodflow [69].
Given the lack of clinical data and the aforementioned
theoretical concern, the use of calcium channel blockers in
PoPH is not recommended.
Beta-blockers
Nonselective beta-blockers are often used in portal hyper-
tension to reduce the risk of variceal bleeding. However,
beta-blockers may impair exercise capacity and cardiovas-
cular hemodynamics because of their negative chronotropic
effects [70]. In a small study, beta-blocker withdrawal in
PoPH was associated with improved exercise capacity and
increased cardiac output [70]. We suggest cautious use of
beta-blockers in PoPH; the clinician should weigh the po-
tential risk of worsening hemodynamics against the benefits
of improving portal hypertension.
Anticoagulants
Unlike other forms of PAH, anticoagulation is contra-
indicated in PoPH because of increased risk of GI bleeding
[3].
Table 5 lists our recommendations concerning the use of
pulmonary vasodilators to treat PoPH.Liver transplantation in PoPH
The presence of moderate to severe pulmonary hyperten-
sion in liver disease patients increases the risk of graft
dysfunction and cardiopulmonary-related mortality after
orthotropic liver transplant (OLT) [71]. For these reasons,
the criteria for liver transplantation and management of
liver transplantation of PoPH patients are highly relevant
issues.
During liver transplantation, there is an acute three-fold
increase in cardiac output from a) relief of portal vein
obstruction by removing the diseased liver; and b) systemicTable 5 Therapy in PoPH.
Agent class Specific medications Utility in PoPH
Prostanoids Epoprostenol þþ
Treprostinil (inhaled,
parenteral)
þþ
Iloprost þþ
ERA’s Bosentan þ
Ambrisentan þþ
PDE-5 Inhibitors Sildenafil þþ
Tadalafil þþ
Ca2þ channel
blockers
All e
Anticoagulants All e
Diuretics All þ
Oxygen N/A þþ
PoPH-portopulmonary hypertension; þþ recommended to use;
þ use with caution; -use is discouraged; N/A not applicable.vasodilation related to anesthesia, ischemia and
reperfusion-induced cytokine release [72]. Given that the
pulmonary vasculature in PoPH is a relatively low compli-
ance and high resistance circuit, this increase in cardiac
output can acutely raise the pulmonary arterial pressure
significantly to precipitate acute RV dysfunction leading to
graft congestion and failure [73e75]. Intraoperative trans-
esophageal echocardiography during OLT may useful to
monitor RV function to detect and treat this complication.
The importance of adequately treating PoPH in patients
undergoing OLT was demonstrated in a retrospective study
of 43 OLT recipients with untreated PoPH who had a car-
diopulmonary mortality proportional to the degree of PH
(Table 6) [75].
The data in Table 6 and additional small studies suggest
that PoPH patients with moderate to severe PH
(35 mmHg) should be treated with vasodilator therapy
before consideration for OLT [51]. In a study of PoPH pa-
tients with moderate to severe PH who were otherwise OLT
candidates, 12 out of 16 (75%) had reduction of mPAP to
<35 mmHg and 11 successfully underwent OLT. One-year
survival was excellent at 91% [50]. The ERS Task Force
Pulmonary-Hepatic Vascular Disorders Scientific Committee
Guidelines state that OLT may be considered in mild pul-
monary hypertension (mPAP < 35 mmHg) with good cardiac
function [3]. In OLT candidates with moderate PH (mPAP
35e45 mmHg), vasodilator therapy should be initiated and
OLT could be considered if the mPAP can be successfully
lowered to or below 35 mmHg. OLT is contraindicated in
PoPH patients with a mPAP 45 mmHg (Fig. 2).
EPO has been effective in reducing the mPAP below
35 mmHg in PoPH patients, thus making these patients
viable candidates for OLT [49e51]. Such patients have been
successfully transplanted with a satisfactory post-
transplant survival.
The response of PoPH to OLT is inconsistent. Some pa-
tients show an improvement in hemodynamics and, occa-
sionally, are able to discontinue vasodilator therapy
[50,76]. However, PoPH often fails to resolve after OLT,
and it is prudent to continue vasodilator therapy immedi-
ately after transplantation. Periodic assessments with
echocardiography and right heart catheterization should be
performed to assess for the presence and severity of PoPH
as well as the need for vasodilator therapy. There are
inadequate data to determine if the outcome from com-
bined liver-lung transplantation is superior to OLT for PoPH.Table 6 Cardiopulmonary mortality associated with Pre-
OLT hemodynamic parameters in untreated PoPH patients
(from Krowka, MJ et al., reference [75]).
Pre-OLT hemodynamic
parameter
Cardiopulmonary
mortality
mPAP >50 mmHg 6/6 (100%)
mPAP > 35 mmHg 14/29 (48%)
mPAP < 35 mmHg 0/14 (0%)
PVR  250 dyn s cm5 11/20 (55%)
PVR <250 dyn s cm5 1/18 (6%)
OLT-orthotopic liver transplantation; mPAP-mean pulmonary
artery pressure; PVR-pulmonary vascular resistance.
Figure 2 ERS Task Force Pulmonary-Hepatic Vascular Disorders Scientific Committee Guidelines for PoPH candidates for OLT [3].
OLT-orthotopic liver transplantation; PoPH-portopulmonary hypertension; mPAP-mean pulmonary artery pressure.
Figure 3 Survival in PoPH. PoPH-portopulmonary hyperten-
sion; IPAH-idiopathic pulmonary arterial hypertension (includes
familial pulmonary arterial hypertension).
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bined liver-lung transplant has been successful [77].
Special considerations in PoPH
Transjugular intrahepatic portosystemic shunt
(TIPS)
TIPS is frequently performed in advanced liver disease pa-
tients for gastrointestinal bleeding who have failed
sclerotherapy or have refractory ascites. However, in small
studies, TIPS has been shown to worsen pulmonary hyper-
tension. As with liver transplantation, TIPS reduces the
resistance in the portal circuit and thereby increases right
ventricular pre-load resulting in an increase in pulmonary
artery pressure [78]. Clinicians need to individualize the
decision to perform TIPS in patients with PoPH, weighing
the benefits of lessening the chance of life-threatening
gastrointestinal bleeding with the risk of worsening pul-
monary hypertension. Therapy for PoPH may need to be
initiated or intensified when TIPS is performed in such
patients.
Prognosis
Individuals with PoPH have a worse outcome compared to
other forms of PAH even when matched for hemodynamic
parameters (Fig. 3) [79]. A dismal median survival of 6
months for PoPH was reported in the era prior to the advent
of specific vasodilator therapy [38]. These prognostic data
are not surprising because PoPH patients have generally
advanced liver disease in addition to pulmonary hyperten-
sion. PoPH patients are less likely to be on a PAH-specific
therapy compared to other PH patients, perhaps due to
lack of studies specifically studying pharmacological therapy
in the PoPHpopulation [80]. The disparity in the treatment of
PoPH and other forms of PHmay contribute to the differencein survival. In support of the need to treat PoPH, Swanson and
colleagues compared survival of PoPH in relation to the use of
medical therapy and/or OLT [81]. Overall, the survival was
better in patients treatedwith eithermedical therapy or OLT
as compared to those who were untreated. The combination
of both interventions was superior to either used alone. The
most common causes of death in PoPH are caused by either
the underlying liver disease and pulmonary hypertension
with a fairly even distribution [82].
The mortality rates for PoPH in the most recent studies
in the past decade are less dire than previously; the
improved survival may be attributable to the wider use of
pulmonary vasodilator therapy and liver transplantation but
952 B.I. Medarov et al.also to increased awareness and early diagnosis (“lead time
bias”) [83]. Because pulmonary vasodilator therapy and
liver transplantation have concomitantly become more
frequent options for PoPH, it is problematic to quantify the
benefit that is specifically attributable to each modality
[81].Summary
PoPH is an important complication of advanced liver dis-
ease. It has a major impact on quality of life and suitability
for liver transplantation. Timely diagnosis is essential to
improve survival, alleviate symptoms and assess the peri-
operative risk of orthotopic liver transplantation. The eti-
ology of PoPH remains unclear and may be related to poor
hepatic clearance of certain metabolites and/or vascular
stress in genetically susceptible individuals. With some
specific nuances, treatment of PoPH is similar to the
treatment of other types of PAH. Medical therapy and OLT
improve survival in PoPH; however, PoPH patients are less
likely to be on medical therapy compared to other forms of
PAH. Raising awareness and specifically targeting the PoPH
population in future studies could improve these patients’
management and further improve our understanding of this
deadly condition.Conflicts of interest
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